Syngene International, a unit of Indian biotechnology major BIOCON Group, has informed that it will offer fully integrated drug discovery services by partnering with Sapient Discovery, a US based Biotechnology Company.

Sapient Discovery uses integrated, proprietary computational and experimental laboratory technologies, and cellular biology and proprietary data mining to accelerate the drug discovery and optimization processes.

It may be noted that Sapient Discovery has in-house lead molecules for infectious disease target as well as for an oncology target and applies its technologies to advance the drug discovery programs of its external partners and clients.

Established in 1994, Syngene provides integrated Chemistry, Biology & Biologics services to support development programs of pharmaceutical & biotech companies worldwide on a platform of confidentiality and intellectual property protection.